Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Nivolumab improves survival in non-small cell lung carcinoma, study results suggest

Taking nivolumab for advanced non-small cell lung carcinoma is associated with a better five-year survival rate than taking docetaxel.

xray lung cancer


A chest X-ray is often the first step in diagnosing non-small cell lung carcinoma

Patients treated with nivolumab for advanced non-small cell lung carcinoma (NSCLC) had a better survival rate at five years than those who received chemotherapy, a follow-up trial has shown[1].

The data included 854 patients who took part in one of two controlled trials (Checkmate 017 and Checkmate 057) where each participant was randomly assigned to nivolumab or docetaxel in a 1:1 ratio. All patients had previously received platinum-based chemotherapy.

At five years, 50 patients treated with nivolumab and 9 patients treated with docetaxel were still alive. The respective overall survival rates were 13% versus 3% and progression-free survival rates were 8% versus 0%.

“Checkmate 017 and [Checkmate] 057 are the first phase III trials to report five-year outcomes for a [programmed cell-death protein 1 (PD-1)] inhibitor in previously treated advanced NSCLC,” said Scott Gettinger, professor of internal at Yale Comprehensive Cancer Center, Connecticut, and lead author of the study. “Nivolumab remained well tolerated with no new safety signals.”

Nivolumab is a PD-1 checkpoint inhibitor. It does not have a marketing authorisation in the EU for previously treated NSCLC, but is available in England through the Cancer Drugs Fund for this indication.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207250

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Community Pharmacy Handbook

    Community Pharmacy Handbook

    Community Pharmacy Handbook is a survival guide for community pharmacists and students, answering your practical questions. Includes case studies.

    £33.00Buy now
  • Lecture Notes in Pharmacy Practice

    Lecture Notes in Pharmacy Practice

    A comprehensive study guide which summarises the basic principles in pharmacy practice. Clear, bulleted information for quick reference.

    £43.00Buy now
  • MCQs in Pharmacy Practice

    MCQs in Pharmacy Practice

    A study aid with 800 MCQs. Assess your knowledge, analytical skills, and ability to apply this knowledge base in clinical practice.

    £25.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £28.00Buy now
  • Chronotherapeutics


    Chronotherapeutics discusses the pharmaceutical and therapeutic implications associated with biological clocks in humans.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.